Zaina Shahid, MD
Rheumatology · Wexford, PANPI 1073171898
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,245 of the $2,508 with a category attached, or 89.5%. 19 manufacturers reported payments, led by Johnson & Johnson at 24.0% of the total. That places this record below the midpoint for rheumatology clinicians in PA, where the typical reported total is $1,951.
Across 109 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$603
- Amgen$406
- AbbVie$312
- Novartis$243
- AstraZeneca$197
- GSK$143
- plus $603 from 13 others
What the payments were for
- Food & beverage$2,24590%
- Education$26310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $603 |
| Amgen | 17 | $406 |
| AbbVie | 18 | $312 |
| Novartis | 14 | $243 |
| AstraZeneca | 9 | $197 |
| GSK | 7 | $143 |
| UCB, Inc. | 5 | $117 |
| Lilly USA, LLC | 4 | $92 |
| Aurinia Pharma U.S., Inc. | 2 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Pfizer | 2 | $41 |
| Sobi, Inc | 2 | $39 |
| Boehringer Ingelheim | 2 | $34 |
| Fresenius Kabi USA, LLC | 2 | $33 |
| Organon | 2 | $33 |
| Sandoz | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Genentech USA, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
How this compares
$2,508 in reported general payments places this provider in the 50th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 11 | $84,148 |
| Hydroxychloroquine Sulfate | 83 | $2,243 |
| MethotrexateMethotrexate Sodium | 43 | $1,453 |
| Colchicine | 27 | $1,393 |
| Prednisone | 61 | $348 |
| Alendronate Sodium | 27 | $326 |
| Allopurinol | 18 | $104 |
| Meloxicam | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Wexford
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
- Frederick MurphyDuncansville$494K
- Peter MerkelRadnor$479K
- Martin BergmanRidley Park$458K
- Alexis Ogdie-BeattyPhiladelphia$433K
- Ellen FieldBethlehem$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.